Published in Eur J Hum Genet on January 16, 2013
A Study of Consent Forms for Whole Exome and Whole Genome Sequencing | NCT01927770
Models of consent to return of incidental findings in genomic research. Hastings Cent Rep (2014) 2.25
Is there a duty to recontact in light of new genetic technologies? A systematic review of the literature. Genet Med (2014) 1.09
Reflecting on earlier experiences with unsolicited findings: points to consider for next-generation sequencing and informed consent in diagnostics. Hum Mutat (2013) 1.04
The challenge of informed consent and return of results in translational genomics: empirical analysis and recommendations. J Law Med Ethics (2014) 1.01
Informed consent for exome sequencing in diagnostics: exploring first experiences and views of professionals and patients. Clin Genet (2013) 1.00
Autonomy and the patient's right 'not to know' in clinical whole-genomic sequencing. Eur J Hum Genet (2013) 0.95
Incidental Findings with Genomic Testing: Implications for Genetic Counseling Practice. Curr Genet Med Rep (2015) 0.89
Practice variation across consent templates for biobank research. a survey of German biobanks. Front Genet (2013) 0.87
Integrating genomics into clinical oncology: ethical and social challenges from proponents of personalized medicine. Urol Oncol (2014) 0.86
"Not Tied Up Neatly with a Bow": Professionals' Challenging Cases in Informed Consent for Genomic Sequencing. J Genet Couns (2015) 0.85
Recommendations for the integration of genomics into clinical practice. Genet Med (2016) 0.85
Informed consent for exome sequencing research in families with genetic disease: the emerging issue of incidental findings. Am J Med Genet A (2014) 0.84
Experiences with obtaining informed consent for genomic sequencing. Am J Med Genet A (2015) 0.83
Researchers' views on informed consent for return of secondary results in genomic research. Genet Med (2014) 0.83
Experience of a multidisciplinary task force with exome sequencing for Mendelian disorders. Hum Genomics (2016) 0.79
Understanding patient and provider perceptions and expectations of genomic medicine. J Surg Oncol (2014) 0.78
A view on clinical genetics and genomics in Spain: of challenges and opportunities. Mol Genet Genomic Med (2016) 0.77
To disclose, or not to disclose? Context matters. Eur J Hum Genet (2014) 0.76
Clinical Genetic Testing in Gastroenterology. Clin Transl Gastroenterol (2016) 0.75
Reply to Townsend et al. Eur J Hum Genet (2013) 0.75
A review of consent practices and perspectives for pharmacogenetic testing. Pharmacogenomics (2016) 0.75
Social and Communicative Functions of Informed Consent Forms in East Asia and Beyond. Front Genet (2017) 0.75
Pediatric Whole Exome Sequencing: an Assessment of Parents' Perceived and Actual Understanding. J Genet Couns (2016) 0.75
Informed consent for next-generation nucleotide sequencing studies: Aiding communication between participants and investigators. J Clin Transl Sci (2017) 0.75
How do providers discuss the results of pediatric exome sequencing with families? Per Med (2017) 0.75
Deploying whole genome sequencing in clinical practice and public health: meeting the challenge one bin at a time. Genet Med (2011) 8.48
Use of whole-genome sequencing to diagnose a cryptic fusion oncogene. JAMA (2011) 4.11
Exploring concordance and discordance for return of incidental findings from clinical sequencing. Genet Med (2012) 4.04
Challenges in the clinical application of whole-genome sequencing. Lancet (2010) 2.92
Opportunities and challenges for the integration of massively parallel genomic sequencing into clinical practice: lessons from the ClinSeq project. Genet Med (2012) 2.83
Downsizing genomic medicine: approaching the ethical complexity of whole-genome sequencing by starting small. Genet Med (2011) 1.93
Intentions to receive individual results from whole-genome sequencing among participants in the ClinSeq study. Eur J Hum Genet (2012) 1.91
To tell or not to tell? A systematic review of ethical reflections on incidental findings arising in genetics contexts. Eur J Hum Genet (2012) 1.82
Personal genomics: information can be harmful. Eur J Clin Invest (2010) 1.54
Whole genome scanning: resolving clinical diagnosis and management amidst complex data. Pediatr Res (2009) 1.29
Personal genomes in progress: from the human genome project to the personal genome project. Dialogues Clin Neurosci (2010) 1.29
The changing landscape of genetic testing and its impact on clinical and laboratory services and research in Europe. Eur J Hum Genet (2012) 1.18
New challenges for informed consent through whole genome array testing. J Med Genet (2009) 1.10
Whole-genome sequencing and the physician. Clin Genet (2012) 1.10
The role of disease characteristics in the ethical debate on personal genome testing. BMC Med Genomics (2012) 0.99
Next generation sequencing--implications for clinical practice. Br Med Bull (2011) 0.96
Ensuring the safe use of genomic medicine in children. Clin Pediatr (Phila) (2009) 0.93
A clinical perspective on ethical issues in genetic testing. Account Res (2011) 0.88
Technological advances in DNA sequence enrichment and sequencing for germline genetic diagnosis. Expert Rev Mol Diagn (2012) 0.87
A personal perspective on returning secondary results of clinical genome sequencing. Genome Med (2012) 0.86
Challenges in clinical genomics. Genome Med (2012) 0.82
Is gene discovery research or diagnosis? Genet Med (2008) 0.81
A novel gene for Usher syndrome type 2: mutations in the long isoform of whirlin are associated with retinitis pigmentosa and sensorineural hearing loss. Hum Genet (2006) 2.27
Importance of local variations in antibiotic consumption and geographical differences of erythromycin and penicillin resistance in Streptococcus pneumoniae. J Clin Microbiol (2002) 1.65
Mutation analysis of 272 Spanish families affected by autosomal recessive retinitis pigmentosa using a genotyping microarray. Mol Vis (2010) 1.64
A genetic basis for mechanosensory traits in humans. PLoS Biol (2012) 1.50
[Is it necessary to change the regulation in which drugs are not the objective of the medical research?]. Med Clin (Barc) (2011) 1.45
[Unified report from committes on Ethics and Clinical Investigations in multicenter trials]. Med Clin (Barc) (2003) 1.43
USH3A transcripts encode clarin-1, a four-transmembrane-domain protein with a possible role in sensory synapses. Eur J Hum Genet (2002) 1.36
Geographical and ecological analysis of resistance, coresistance, and coupled resistance to antimicrobials in respiratory pathogenic bacteria in Spain. Antimicrob Agents Chemother (2005) 1.34
BBS genotype-phenotype assessment of a multiethnic patient cohort calls for a revision of the disease definition. Hum Mutat (2011) 1.28
Mutation update of spinal muscular atrophy in Spain: molecular characterization of 745 unrelated patients and identification of four novel mutations in the SMN1 gene. Hum Genet (2008) 1.17
Glucose metabolism in patients with essential hypertension. Am J Med (2006) 1.16
Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007). Antimicrob Agents Chemother (2010) 1.15
[Validation of the Spanish versions of the Montgomery-Asberg depression and Hamilton anxiety rating scales]. Med Clin (Barc) (2002) 1.04
Identification of large rearrangements of the PCDH15 gene by combined MLPA and a CGH: large duplications are responsible for Usher syndrome. Invest Ophthalmol Vis Sci (2010) 1.02
Mutations in chaperonin-like BBS genes are a major contributor to disease development in a multiethnic Bardet-Biedl syndrome patient population. J Med Genet (2010) 1.02
Genetic diagnosis of X-linked dominant Hypophosphatemic Rickets in a cohort study: tubular reabsorption of phosphate and 1,25(OH)2D serum levels are associated with PHEX mutation type. BMC Med Genet (2011) 0.94
Plastin 3 expression in discordant spinal muscular atrophy (SMA) siblings. Neuromuscul Disord (2011) 0.92
Sequence variants of the DFNB31 gene among Usher syndrome patients of diverse origin. Mol Vis (2010) 0.90
Sleep laboratory study on single and repeated dose effects of paroxetine, alprazolam and their combination in healthy young volunteers. Neuropsychobiology (2005) 0.89
Calcific retropharyngeal tendinitis: a frequently missed diagnosis. Case report. J Neurosurg Spine (2007) 0.88
The USH2A c.2299delG mutation: dating its common origin in a Southern European population. Eur J Hum Genet (2010) 0.87
Survey of emm-like gene sequences from pharyngeal isolates of group C and group G streptococci collected in Spain. J Clin Microbiol (2005) 0.86
Sensitivity to change, discriminative performance, and cutoff criteria to define remission for embedded short scales of the Hamilton depression rating scale (HAMD). J Affect Disord (2007) 0.85
Mutation screening of the PCDH15 gene in Spanish patients with Usher syndrome type I. Mol Vis (2012) 0.85
[A comparative psychometric study of the Spanish versions with 6, 17, and 21 items of the Hamilton Depression Rating Scale]. Med Clin (Barc) (2003) 0.85
Ancient origin of the CAG expansion causing Huntington disease in a Spanish population. Hum Mutat (2005) 0.82
CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment. Pharmacogenet Genomics (2013) 0.82
Brainstem stroke: anatomy, clinical and radiological findings. Semin Ultrasound CT MR (2013) 0.81
ATA homozigosity in the IL-10 gene promoter is a risk factor for schizophrenia in Spanish females: a case control study. BMC Med Genet (2011) 0.81
Age does not appear to be a major indicator of CDKN2A or CDK4 mutations in melanoma patients in Spain. Melanoma Res (2005) 0.80
[A validation study of the Spanish versions of the Clinical Anxiety Scale and the Physician Questionnaire for the assessment of anxiety disorders]. Med Clin (Barc) (2003) 0.79
Lack of pharmacologic interaction between paroxetine and alprazolam at steady state in healthy volunteers. J Clin Psychopharmacol (2004) 0.78
Clinical trials committees: how long is the protocol review and approval process in Spain? A prospective study. IRB (1996) 0.78
Infliximab reduces Zaprinast-induced retinal degeneration in cultures of porcine retina. J Neuroinflammation (2014) 0.78
Evaluating a newly developed pharmacogenetic array: screening in a Spanish population. Pharmacogenomics (2010) 0.78
Two novel disease-causing mutations in the CLRN1 gene in patients with Usher syndrome type 3. Mol Vis (2012) 0.75
Analysis of the Ush2a gene in medaka fish (Oryzias latipes). PLoS One (2013) 0.75
Clinical and bacteriological implications of macrolide resistance in group A streptococcal pharyngitis. J Antimicrob Chemother (2003) 0.75
[Pharmacogenetic studies assessment in clinical research: Four issues, four opinions]. Med Clin (Barc) (2010) 0.75
Gene symbol: SH3TC2. Disease: Charcot-Marie-Tooth type 4C. Hum Genet (2008) 0.75
[Is it ethical conducting placebo-controlled clinical trials as part of the development of new drugs for the treatment of major depressive disorder? (I). Considerations on the value and scientific validity of the study]. Med Clin (Barc) (2004) 0.75
[Ethics on genetic research (1). Pharmacogenetic studies]. Med Clin (Barc) (2009) 0.75
[How long is it necessary to begin a multicentric clinical trial in Spain?]. Med Clin (Barc) (2007) 0.75
Reactogenicity profile of a combined hepatitis A and B vaccine in clinical practice: a naturalistic study in adult travellers. Vaccine (2005) 0.75
[Informing participants on study results and the Declaration of Helsinki 2008]. Med Clin (Barc) (2009) 0.75
[Usher syndrome: an example of genetic heterogeneity]. Med Clin (Barc) (2005) 0.75
[Informed consent in clinical trials and pharmacogenetic substudies]. Med Clin (Barc) (2010) 0.75